Stephen Sides, DO
Rheumatology · Jefferson City, MONPI 1366428914
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (43.2%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 32 manufacturers reported payments, led by Janssen Scientific Affairs, LLC at 56.6% of the total. Reporting peaked in 2022 at $7,475 and has fallen 88.6% since, to $856 in 2025.
Across 416 payments — averaging $27.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Scientific Affairs, LLC$6K
- Amgen$1K
- AbbVie$980
- Johnson & Johnson$778
- AstraZeneca$540
- Pfizer$400
- plus $1K from 26 others
Across 3 payments — averaging $12,884 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$39K
What the payments were for
- Consulting fees$4,27137%
- Travel & lodging$2,05418%
- Food & beverage$4,95243%
- Education$1742%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Scientific Affairs, LLC | 8 | $6,483 |
| Amgen | 112 | $1,161 |
| AbbVie | 117 | $980 |
| Johnson & Johnson | 53 | $778 |
| AstraZeneca | 21 | $540 |
| Pfizer | 39 | $400 |
| GSK | 20 | $290 |
| Novo Nordisk | 9 | $140 |
| Merck | 4 | $69 |
| Radius Health, Inc. | 3 | $61 |
| Dexcom, Inc. | 2 | $48 |
| Xeris Pharmaceuticals, Inc. | 2 | $39 |
| Pharmacosmos Therapeutics Inc. | 2 | $39 |
| Lilly USA, LLC | 2 | $38 |
| Astellas Pharma US Inc | 2 | $37 |
| Sumitomo Pharma America, Inc. | 2 | $35 |
| Daiichi Sankyo Inc. | 2 | $33 |
| Vertex | 1 | $28 |
| Medtronic | 1 | $26 |
| Novartis | 2 | $26 |
| Sandoz | 1 | $23 |
| Genentech USA, Inc. | 1 | $22 |
| ADMA Biomanufacturing LLC | 1 | $21 |
| Biogen | 1 | $17 |
| UCB, Inc. | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Sanofi Pasteur Inc. | 1 | $16 |
| Averitas Pharma Inc. | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Melinta Therapeutics, LLC | 1 | $14 |
| Bayer | 1 | $13 |
| Phathom Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,451 in reported general payments places this provider in the 80th percentile of 134 rheumatology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 92 | $986,762 |
| Enbrel SureclickEtanercept | 107 | $927,674 |
| Humira(Cf)Adalimumab | 29 | $337,863 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 44 | $334,718 |
| Xeljanz XrTofacitinib Citrate | 41 | $333,601 |
| OtezlaApremilast | 53 | $294,464 |
| Orencia ClickjectAbatacept | 41 | $285,407 |
| EnbrelEtanercept | 20 | $252,855 |
| TremfyaGuselkumab | 17 | $244,302 |
| Humira PenAdalimumab | 16 | $116,483 |
| Hydroxychloroquine Sulfate | 1,043 | $35,029 |
| MethotrexateMethotrexate Sodium | 937 | $25,355 |
| AvsolaInfliximab-Axxq | 13 | $20,671 |
| OtrexupMethotrexate/Pf | 13 | $9,690 |
| Mycophenolate Mofetil | 67 | $7,396 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla, Enbrel, Avsola | $1,161 | $567,99086 claims |
| AbbVieHumira(Cf) | $980 | $337,86329 claims |
| Johnson & JohnsonTremfya | $778 | $244,30217 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 134 rheumatology providers in Missouri.
Other rheumatology in Jefferson City
- Anne WinklerCarthage$1.6M
- Adam KilianSaint Louis$565K
- Alfred KimSaint Louis$486K
- Mark BoxKansas City$304K
- Sona KamatSaint Louis$268K
- Robert JacksonMemphis$152K
- Richard BrasingtonSaint Louis$100K
- Michael JosephJoplin$94K
- Ghaith NoaisehKansas City$69K
- Thomas ScottKansas City$48K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.